Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis (Q35212994)

7 August 2017

1 reference

title

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis (English)

1 reference

7 August 2017

3

Hans-Peter Hartung

1 reference

7 August 2017

2

Olaf Stüve

1 reference

7 August 2017

5

Bernd C Kieseier

1 reference

7 August 2017

Clemens Warnke

1

1 reference

7 August 2017

Anna Fogdell-Hahn

series ordinal

4

1 reference

7 August 2017

language of work or name

English

0 references

publication date

8 September 2011

1 reference

Neuropsychiatric Disease and Treatment

7 August 2017

published in

1 reference

7 August 2017

volume

7

1 reference

7 August 2017

page(s)

519-527

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

7 August 2017

copyright license

start time

1 September 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Principles of a new treatment algorithm in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Impact of sphingosine 1-phosphate modulation on immune outcomes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Fingolimod is a potential novel therapy for multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

The changing demographic pattern of multiple sclerosis epidemiology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Natalizumab for multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173035

Transforming multiple sclerosis trials into practical reality

26 September 2018

1 reference

12 December 2020

[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]

1 reference

12 December 2020

Delayed fingolimod-associated asystole

1 reference

12 December 2020

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

1 reference

12 December 2020

Predicting the development of multiple sclerosis: is gray matter a missing piece of the puzzle?

1 reference

12 December 2020

The predictive value of gray matter atrophy in clinically isolated syndromes

1 reference

12 December 2020

Altered CD4 /CD8 T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.2147/NDT.S10481

1 reference

7 August 2017

1 reference

7 August 2017

1 reference